NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $11.52 +0.58 (+5.30%) Closing price 04:00 PM EasternExtended Trading$11.45 -0.07 (-0.62%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Gossamer Bio Stock (NASDAQ:GOSS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$10.33▼$11.8550-Day Range$10.38▼$16.5452-Week Range$9.10▼$309.60Volume516,355 shsAverage Volume233,765 shsMarket Capitalization$70.39 millionP/E RatioN/ADividend YieldN/APrice Target$256.00Consensus RatingHold Company Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions. Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling. The company is evaluating seralutinib in clinical studies as a potential treatment for pulmonary arterial hypertension and related cardiopulmonary disorders. Founded in 2015 and headquartered in San Diego, California, Gossamer Bio operates primarily through research, clinical development and collaborations with biotechnology and pharmaceutical partners. Its programs are intended for patients in the United States and international markets, subject to clinical and regulatory review.AI Generated. May Contain Errors. Read More Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 469th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingGossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialGossamer Bio has a consensus price target of $256.00, representing about 2,122.2% upside from its current price of $11.52.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($32.90) to ($15.09) per share.Read more about Gossamer Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted33.73% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 5.07.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 98.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.40 News SentimentGossamer Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Gossamer Bio this week, compared to 8 articles on an average week.Search InterestOnly 5 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by Insiders4.15% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOSS Stock News HeadlinesHC Wainwright Forecasts Stronger Earnings for Gossamer BioSeptember 25 at 1:13 AM | americanbankingnews.comGossamer Bio, Inc. Submits New Drug Application to U.S. Fda for Seralutinib for Treatment of Pulmonary Arterial HypertensionSeptember 24, 2026 | marketscreener.comMAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 28 at 1:00 AM | Stansberry Research (Ad)Gossamer Bio, Inc. reicht bei der US-FDA einen Zulassungsantrag für Seralutinib zur Behandlung von pulmonaler arterieller Hypertonie einSeptember 24, 2026 | de.marketscreener.comDGossamer Bio Files New Drug Application for SeralutinibSeptember 24, 2026 | finance.yahoo.comGossamer Bio Files First NDA for Seralutinib PAH DrugSeptember 23, 2026 | tipranks.comGossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial HypertensionSeptember 23, 2026 | businesswire.comHC Wainwright Boosts Gossamer Bio (NASDAQ:GOSS) Price Target to $90.00September 21, 2026 | americanbankingnews.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $248.00 at the beginning of 2026. Since then, GOSS stock has decreased by 95.4% and is now trading at $11.52. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings results on Friday, May, 15th. The company reported ($16.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($13.60) by $2.40. The business had revenue of $16.96 million for the quarter, compared to the consensus estimate of $4.67 million. Read the conference call transcript. When did Gossamer Bio's stock split? Gossamer Bio shares reverse split on the morning of Friday, September 11th 2026.A 1-80 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 10th 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional shareholders include GSA Capital Partners LLP (6.39%), ARCH Venture Management LLC (3.43%), BlackRock Inc. (3.27%) and Corient Private Wealth LP (2.40%). Insiders that own company stock include Faheem Hasnain, Richard Aranda and Bryan Giraudo. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/15/2026Today9/28/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GOSS's financial health is in the Red zone, according to TradeSmith. GOSS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees162Year Founded2015Price Target and Rating Average Price Target for Gossamer Bio$256.00 High Price Target$720.00 Low Price Target$80.00 Potential Upside/Downside+2,122.2%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($56.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$170.37 million Net Margins-235.00% Pretax Margin-235.17% Return on EquityN/A Return on Assets-112.04% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$48.47 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value($42.43) per share Price / Book-0.27Miscellaneous Outstanding Shares6,110,000Free Float5,857,000Market Cap$70.39 million OptionableOptionable Beta2.00 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:GOSS) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
